LJP 920

Drug Profile

LJP 920

Alternative Names: LJP-920

Latest Information Update: 06 Mar 2013

Price : $50

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Xenotransplant rejection

Most Recent Events

  • 07 Jan 2004 No development reported - Preclinical for Xenotransplant rejection in USA (unspecified route)
  • 27 Aug 2001 A preclinical study has been added to the pharmacokinetics section
  • 10 Jan 2000 Results of an animal study have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top